Table 1.
Summary of the included treatment comparisons.
| Trial | Year recruitment started | Intervention (platinum-containing) | Control | Platinum agent | Same backbone? | Adjuvant or neoadjuvant | Hormone receptor IHC cut-off |
|---|---|---|---|---|---|---|---|
| ADAPT-TN[13] | 2013 | Nab-paclitaxel 125 mg/m2 + carboplatin AUC2 days 1 and 8 every 3 weeks for 4 cycles | Nab-paclitaxel 125 mg/m2 + gemcitabine 1000 mg/m2 days 1 and 8 every 3 weeks for 4 cycles | Carboplatin AUC2 every week (days 1 and 8 every 21 days) | No | Neoadjuvant | <1% |
| Ando 2014[14] | 2010 | Carboplatin AUC5 every 3 weeks for 4 cycles + paclitaxel 80 mg/m2 days 1, 8, 15 for 4 cycles, followed by 4 cycles of cyclophosphamide 500 mg/m2, epirubicin 100 mg/m2 and fluorouracil 500 mg/m2 every 3 weeks | Paclitaxel 80 mg/m2 days 1, 8, 15 for 4 cycles followed by 4 cycles of cyclophosphamide 500 mg/m2, epirubicin 100 mg/m2 and fluorouracil 500 mg/m2 every 3 weeks | Carboplatin AUC5 every 3 weeks | Yes | Neoadjuvant | <10% |
| BrighTNess comparison 1 [12] | 2014 | Paclitaxel 80 mg/m2 weekly + carboplatin AUC6 every 3 weeks for 12 weeks + veliparib 50 mg twice a day, followed by doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 or 3 weeks for 4 cycles | Paclitaxel 80 mg/m2 weekly for 12 weeks, followed by doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 or 3 weeks for 4 cycles | Carboplatin AUC6 every 3 weeks | Yes | Neoadjuvant | <1% |
| BrighTNess comparison 2 [12] | 2014 | Paclitaxel 80 mg/m2 weekly + carboplatin AUC6 every 3 weeks for 12 weeks, followed by doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 or 3 weeks for 4 cycles | Paclitaxel 80 mg/m2 weekly for 12 weeks, followed by doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 or 3 weeks for 4 cycles | Carboplatin AUC6 every 3 weeks | Yes | Neoadjuvant | <1% |
| CALGB 40603 [15] | 2009 | Paclitaxel 80 mg/m2 weekly + carboplatin AUC6 every 3 weeks for 12 weeks followed by doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 2 weeks for 4 cycles ± bevacizumab 10 mg/kg every 2 weeks for 9 cycles | Paclitaxel 80 mg/m2 weekly for 12 weeks followed by doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 2 weeks for 4 cycles ± bevacizumab 10 mg/kg every 2 weeks for 9 cycles | Carboplatin AUC6 every 3 weeks | Yes | Neoadjuvant | <10% |
| GEICAM 2006-03[16] | 2007 | Epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles followed by docetaxel 75 mg/m2 + carboplatin AUC6 every 3 weeks for 4 cycles | Epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles followed by docetaxel 75 mg/m2 every 3 weeks for 4 cycles | Carboplatin AUC6 every 3 weeks | Yes | Neoadjuvant | Not described |
| GeparOcto[17] | 2014 | Paclitaxel 80 mg/m2 + non-pegylated liposomal doxorubicin 20 mg/m2 + carboplatin AUC1.5 weekly for 18 weeks | Epirubicin 150 mg/m2 + paclitaxel 225 mg/m2 + cyclophosphamide 2000 mg/m2 every 2 weeks for 3 cycles | Carboplatin AUC1.5 every week | No | Neoadjuvant | <1% |
| GeparOLA[18] | 2016 | Paclitaxel 80 mg/m2 + carboplatin AUC2 weekly for 12 weeks followed by epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2 every 2 or 3 weeks for 4 cycles | Paclitaxel 80 mg/m2 weekly + olaparib 100 mg twice a day for 12 weeks followed by epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2 every 2 or 3 weeks for 4 cycles | Carboplatin AUC2 every week | No | Neoadjuvant | <1% |
| GeparSixto[19] | 2011 | Carboplatin AUC2 or 1.5 + paclitaxel 80 mg/m2 + non-pegylated liposomal doxorubicin 20 mg/m2 + bevacizumab 15 mg/kg every 3 weeks for 18 weeks | Paclitaxel 80 mg/m2 + non-pegylated liposomal doxorubicin 20 mg/m2 weekly + bevacizumab 15 mg/kg every 3 weeks for 18 weeks | Carboplatin AUC1.5 or 2 every week | Yes | Neoadjuvant | <1% |
| Gigolaeva 2019 [20] | NR | Doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles followed by carboplatin AUC2 weekly + eribulin 1.4 mg/m2 or paclitaxel 175 mg/m2 every 3 weeks for 12 weeks | Doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles followed by paclitaxel 80 mg/m2 for 12 weeks | Carboplatin AUC2 every week | No | Neoadjuvant | Not described |
| INFORM[21] | 2012 | Cisplatin 75 mg/m2 every 3 weeks for 4 cycles | Doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 2–3 weeks for 4 cycles | Cisplatin 75 mg/m2 every 3 weeks | No | Neoadjuvant | <10% |
| I-SPY2 [22] | 2010 | Paclitaxel 80 mg/m2 weekly + veliparib 50 mg twice daily + carboplatin AUC6 every 3 weeks for 12 weeks followed by doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 2 or 3 weeks for 4 cycles | Paclitaxel 80 mg/m2 weekly for 12 weeks followed by doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 2 or 3 weeks for 4 cycles | Carboplatin AUC6 every 3 weeks | No | Neoadjuvant | <5% |
| Li 2020 [23] | 2011 | Paclitaxel 150 mg/m2 + carboplatin AUC3 every 2 weeks for 8 cycles | Epirubicin 80 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks for 4 cycles followed by paclitaxel 175 mg/m2 every 2 weeks for 4 cycles | Carboplatin AUC3 every 2 weeks | No | Adjuvant | <1% |
| Nasr 2015[24] | 2008 | 5-fluorouracil 500 mg/m2 + epirubicin 100 mg/m2 + cyclophosphamide 500 mg/m2 every 3 weeks for 3 cycles then docetaxel 80 mg/m2 + carboplatin AUC5 every 3 weeks for 3 cycles, followed by postoperative radiotherapy, followed by cyclophosphamide 50 mg daily and methotrexate 2.5 mg twice daily on days 1, 2 of each week for 1 year | 5-fluorouracil 500 mg/m2 + epirubicin 100 mg/m2 + cyclophosphamide 500 mg/m2 every 3 weeks for 3 cycles then docetaxel 80 mg/m2 every 3 weeks for 3 cycles | Carboplatin AUC5 every 3 weeks | No | Adjuvant | Not described |
| NeoCART[25] | 2016 | Docetaxel 75 mg/m2 + carboplatin AUC6 every 3 weeks for 6 cycles | Epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles followed by docetaxel 100 mg/m2 every 3 weeks for 4 cycles | Carboplatin AUC6 every 3 weeks | No | Neoadjuvant | <1% |
| PATTERN[26] | 2011 | Paclitaxel 80 mg/m2 + carboplatin AUC2 days 1, 8, 15, every 28 days for 6 cycles | Cyclophosphamide 500 mg/m2 + epirubicin 100 mg/m2 + fluorouracil 500 mg/m2 every 3 weeks for 3 cycles followed by docetaxel 100 mg/m2 every 3 weeks for 3 cycles | Carboplatin AUC2 every week (days 1, 8, 15 every 28 days) | No | Adjuvant | <1% |
| TBCRC 030 [27] | 2014 | Cisplatin 75 mg/m2 every 3 weeks for 4 cycles | Doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 every 2 weeks for 4 cycles | Cisplatin 75 mg/m2 every 3 weeks | No | Neoadjuvant | <5% |
| Wu 2018[28] | 2014 | Lobaplatin 30 mg/m2 for 4 cycles + epirubicin 80 mg/m2 + docetaxel 75 mg/m2 every 3 weeks presurgery and 2 cycles postsurgery | Epirubicin 80 mg/m2 for 4 cycles + docetaxel 75 mg/m2 every 3 weeks presurgery and 2 cycles postsurgery | Lobaplatin 30 mg/m2 every 3 weeks | Yes | Both | <10% |
| Zhang 2016[29] | 2006 | Paclitaxel 175 mg/m2 + carboplatin AUC5 every 3 weeks for 4–6 cycles | Epirubicin 75 mg/m2 + paclitaxel 175 mg/m2 every 3 weeks for 4–6 cycles | Carboplatin AUC5 every 3 weeks | No | Neoadjuvant | <10% |
| Zhao 2014[30] | Not provided in translation | Paclitaxel 175 mg/m2 day 1, carboplatin AUC5 day 2, every 3 weeks for 2 cycles | Epirubicin 75 mg/m2 day 1, paclitaxel 175 mg/m2 day 2, every 3 weeks for 2 cycles | Carboplatin AUC5 every 3 weeks | No | Neoadjuvant | Not provided in translation |
| Zheng 2022[31] | 2009 | Docetaxel 75 mg/m2 or paclitaxel 175 mg/m2 + carboplatin AUC5 every 3 weeks for 6 cycles | Epirubicin 90 mg/m2 + cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles, followed by docetaxel 75 mg/m2 or paclitaxel 175 mg/m2 every 3 weeks for 4 cycles | Carboplatin AUC5 every 3 weeks | No | Adjuvant | <1% |
AUC: area under the curve; IHC: immunohistochemistry. A single trial reference has been included for each of the included studies; a full list of reviewed study records can be found in the original article https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD014805.pub2/full